For Research Purposes Only

UK availability guide

PT-141 (Bremelanotide) in the UK: the research peptide explained

PT-141 is the best-known melanocortin-4 receptor compound in peptide research — and the only one with a licensed medicine sibling. This page covers what PT-141 is, how it relates to MT-2 and Vyleesi, and its UK legal position. For laboratory research use only.

MC4-receptor research compound

A cyclic heptapeptide studied at melanocortin receptors, central to CNS-signalling research designs.

Third-party tested

Independent verification of identity and purity on every batch, with certificates of analysis available.

Tracked UK delivery

Same-day dispatch before cut-off with tracked delivery in temperature-controlled packaging.

PT-141 in the melanocortin research family

The melanocortin system — five receptors (MC1–MC5) activated by fragments of pro-opiomelanocortin — is one of the most actively studied signalling families in peptide research. PT-141 occupies a specific niche: unlike Melanotan 2, from which it derives, its research profile centres on MC4-receptor activity in the central nervous system rather than pigmentation pathways. Its journey from research compound to licensed medicine (as Vyleesi in the US) also makes it a frequently cited case study in peptide drug development.

Melanocortin research peptides

PT-141 and MT-2, supplied for laboratory research use with batch-level third-party testing and certificates of analysis available.

Frequently asked questions

What is PT-141?

Is PT-141 the same as Vyleesi?

Is PT-141 legal in the UK?

How is PT-141 related to Melanotan 2?

Is RegenMed PT-141 third-party tested?

Related reading

All products sold by RegenMed are supplied strictly for laboratory research purposes only and are not for human consumption. Nothing on this page is medical advice, and no statement has been evaluated by the MHRA or FDA. Content summarising published research is provided for educational purposes.